title: Antiangiogenic therapy improves the antitumor effect of adoptive cell immunotherapy by normalizing tumor vasculature.
abstract: Abnormal tumor vasculature and subsequent tumor hypoxia contribute to immune tolerance of tumor cells by impeding the homing of cytotoxic T cells into tumor parenchyma and inhibiting their antitumor efficacy. These obstacles might explain why the promising approach of adoptive cell immunotherapy does not exert significant antitumor activity. Hypoxia contributes to immune suppression by activating hypoxia-inducible factor (HIF-1) and the vascular endothelial growth factor pathway, which plays a determining role in promoting tumor cell growth and survival. Tumor hypoxia creates an immunosuppressive microenvironment via the accumulation and subsequent polarization of inflammatory cells toward immune suppression phenotypes, such as myeloid-derived suppressor cells, tumor-associated macrophages, and dendritic cells. Antiangiogenic therapy could normalize tumor vasculature and decrease hypoxic tumor area and thus may be an effective modality to potentiate immunotherapy. Adoptive cell immunotherapy alone is not efficient enough to decrease tumor growth as its antitumor effect is inhibited by the immunosuppressive hypoxic tumor microenvironment. This review describes that combination of antiangiogenic therapy with adoptive cell immunotherapy can exert synergistic antitumor effect, which will contribute to improve strategies for future anticancer therapies.
authors: Medical Oncology Department of Jinling Hospital, Medical School of Nanjing University, Nanjing, People's Republic of China, shishuojing@gmail.com.
authors: Shujing
authors: S
authors: Shi
authors: Longbang
authors: L
authors: Chen
authors: Guichun
authors: G
authors: Huang
mesh_terms: D020533:Angiogenesis Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use*; D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use*; D003131:Combined Modality Therapy / Q000379:methods; D006801:Humans; D016219:Immunotherapy, Adoptive / Q000379:methods*; D009369:Neoplasms / Q000188:drug therapy*; D009389:Neovascularization, Pathologic / Q000188:drug therapy*
chemical_list: D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents
references: Technol Cancer Res Treat. 2013 Jun;12(3):259-67
references: 23289476
references: Nature. 2008 May 15;453(7193):410-4
references: 18418378
references: Nat Rev Immunol. 2003 Dec;3(12):984-93
references: 14647480
references: Nat Med. 2001 Sep;7(9):987-9
references: 11533692
references: Cancer Immunol Immunother. 2011 Mar;60(3):319-26
references: 21267721
references: FASEB J. 2006 Apr;20(6):621-30
references: 16581970
references: PLoS One. 2013 Jun 14;8(6):e65757
references: 23799045
references: J Exp Med. 2010 Oct 25;207(11):2439-53
references: 20876310
references: Cancer Lett. 2013 May 10;332(1):3-10
references: 23348699
references: N Engl J Med. 2005 Dec 22;353(25):2654-66
references: 16371631
references: Blood. 2004 Oct 15;104(8):2224-34
references: 15231578
references: Nat Immunol. 2000 Sep;1(3):199-205
references: 10973276
references: PLoS One. 2013;8(2):e57114
references: 23437326
references: Cancer Biother Radiopharm. 2008 Oct;23(5):661-7
references: 18986217
references: Proc Natl Acad Sci U S A. 2012 Oct 23;109(43):17561-6
references: 23045683
references: Blood. 2008 Sep 1;112(5):1822-31
references: 18559975
references: Cell. 2011 Mar 4;144(5):646-74
references: 21376230
references: Cancer Res. 2013 Apr 15;73(8):2435-44
references: 23423978
references: Science. 2006 Sep 29;313(5795):1960-4
references: 17008531
references: Physiol Rev. 2011 Jul;91(3):1071-121
references: 21742796
references: Proc Natl Acad Sci U S A. 2008 Sep 2;105(35):12643-4
references: 18753635
references: Clin Cancer Res. 2012 Mar 1;18(5):1207-13
references: 22205687
references: Expert Rev Mol Diagn. 2011 Jan;11(1):91-100
references: 21171924
references: Cancer Res. 2010 Aug 1;70(15):6171-80
references: 20631075
references: J Immunol. 2013 Apr 1;190(7):3783-97
references: 23440412
references: Science. 2005 Jan 7;307(5706):58-62
references: 15637262
references: Clin Cancer Res. 2011 May 15;17(10):3134-45
references: 21252159
references: Immunology. 2009 Sep;128(1 Suppl):e237-49
references: 19740309
references: Clin Cancer Res. 2007 Jul 1;13(13):3951-9
references: 17606729
references: J Clin Invest. 2010 Nov;120(11):3953-68
references: 20978347
references: Cancer Cell. 2011 Jan 18;19(1):31-44
references: 21215706
references: Blood. 2011 Nov 17;118(20):5371-9
references: 21856865
references: Proc Natl Acad Sci U S A. 2006 Aug 29;103(35):13132-7
references: 16916931
references: Microvasc Res. 2007 Sep-Nov;74(2-3):72-84
references: 17560615
references: PLoS One. 2012;7(12):e50946
references: 23284651
references: PLoS One. 2011;6(8):e23108
references: 21853076
references: Clin Cancer Res. 2012 Apr 1;18(7):2039-47
references: 22271879
references: Cytotherapy. 2012 Jan;14(1):91-103
references: 21973023
references: Onco Targets Ther. 2013;6:53-8
references: 23378775
references: Crit Care Med. 1994 Feb;22(2):197-203
references: 8306676
references: Cancer Invest. 2013 Mar;31(3):197-205
references: 23477587
references: Nature. 2004 Feb 19;427(6976):695
references: 14973470
references: PLoS One. 2013;8(1):e55818
references: 23383287
references: Cancer Biother Radiopharm. 2009 Oct;24(5):589-96
references: 19877889
references: Expert Opin Ther Targets. 2011 May;15(5):609-21
references: 21388336
references: Front Immunol. 2012 Feb 23;3:21
references: 22566905
references: Oncogene. 2010 Feb 25;29(8):1093-102
references: 19946335
references: J Natl Cancer Inst. 1989 Apr 19;81(8):570-6
references: 2649688
references: Int J Dev Biol. 2011;55(7-9):861-7
references: 22161841
references: J Cancer Res Clin Oncol. 2010 Aug;136(8):1201-11
references: 20130910
references: Cancer Res. 2013 May 1;73(9):2782-94
references: 23418320
references: J Pathol. 2000 Oct;192(2):150-8
references: 11004690
references: Immunol Rev. 2008 Apr;222:162-79
references: 18364001
references: Immunol Cell Biol. 2010 Feb;88(2):165-71
references: 19841638
references: Mol Ther. 2008 Mar;16(3):599-606
references: 18227840